London – Saba:
Researchers have announced the development of a new drug called tepilizumab, which has shown promising potential to delay the onset of type 1 diabetes by several years, a step that could change the course of treatment for this chronic autoimmune disease.
The drug works by reprogramming the immune system and reducing the activity of immune cells that attack insulin-producing pancreatic cells, the first patient in the United Kingdom has begun receiving this treatment.
Researchers have announced the development of a new drug called tepilizumab, which has shown promising potential to delay the onset of type 1 diabetes by several years, a step that could change the course of treatment for this chronic autoimmune disease.
The drug works by reprogramming the immune system and reducing the activity of immune cells that attack insulin-producing pancreatic cells, the first patient in the United Kingdom has begun receiving this treatment.